compelling clinical data
fuels our platform

The microbiome:
Essential for health.
Harnessed for medicine.

The microbiome consists of trillions of microbes that live symbiotically in and on every human and are essential to our health. When key microbes are lost, the resulting dysbiosis (microbiome disruption) can increase susceptibility to immune disorders, infections, neurological conditions, cancer, and other serious conditions. We are leveraging our Human-First Discovery® platform to develop novel therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the conditions that emerge from it.

Our Human-First Discovery platform & product strategies

Our platform is fueled by data from human microbiota transplantation studies. These studies involve the transfer of microbiota from healthy individuals to individuals with disease, an area of intense research with hundreds of studies spanning dozens of different conditions. We leverage data from these types of studies, plus machine learning and molecular characterization techniques, to identify conditions where a disrupted microbiome is driving disease and to uncover the key dynamics associated with successful clinical outcomes.

Our platform enables the development of product candidates that deliver complete microbiome communities to restore broad community function and candidates that contain select microbes targeting specific biological pathways. This combination of capabilities uniquely positions us to develop three different types of candidates designed to address different types of dysbiosis that lead to microbiome-mediated conditions.

Complete Consortia

Delivers complete microbial community to restore broad community function

Enriched Consortia

Hybrid approach to restore broad community function and target specific pathways

Targeted Consortia

Delivers selected microbes to target specific biological pathways


Our Human-First Discovery platform enables:

De-Risking of Programs

The design of our product candidates is driven by reverse translation from successful human microbiota transplantation studies, avoiding the translational risk associated with approaches that rely upon in vitro or animal models of disease to drive candidate selection.

Accelerated Development & Pipeline Expansion

We believe we can rapidly enter the clinic with CP101, our Complete Consortia product candidate, allowing us to evaluate the use of a microbiome therapeutic for the treatment of conditions that already have shown promising proof-of-concept data. Our plans for accelerated development of CP101 have the potential to allow us to develop therapeutics intended to address unmet needs quickly, while simultaneously generating robust datasets that can be leveraged to fuel the development of second-generation therapeutics.

Development of Potentially Disease-Modifying Drugs

Microbiome drugs have the potential to be disease-modifying agents, addressing the underlying cause of a condition rather than just treating the symptoms. For example, in recurrent C. difficile infection, microbiome therapeutics address the root cause of recurrence by restoring the diversity of the microbiome and colonization resistance.

An industry leading IP portfolio

Our platform is supported by a large and diverse patent portfolio that consists of more than 50 issued U.S. and foreign patents, as well as more than 130 patent applications, that embodies pioneering work in the microbiome field.

Supporting literature